Discovery of peroxisome proliferator–activated receptor α (PPARα) activators with a ligand-screening system using a human PPARα-expressing cell line

• Published in: The Journal of biological chemistry Vol. 293; no. 26; pp. 10333 - 10343
• Main Authors: Tachibana, Keisuke, Yuzuriha, Tomohiro, Tabata, Ryotaro, Fukuda, Syohei, Maegawa, Takashi, Takahashi, Rika, Tanimoto, Keiichi, Tsujino, Hirofumi, Nunomura, Kazuto, Lin, Bangzhong, Matsuura, Yoshiharu, Tanaka, Toshiya, Hamakubo, Takao, Sakai, Juro, Kodama, Tatsuhiko, Kobayashi, Tadayuki, Ishimoto, Kenji, Miyachi, Hiroyuki, Doi, Takefumi
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 29.06.2018; American Society for Biochemistry and Molecular Biology
• Subjects: Animals; cell biology; chemical screening system; Drug Evaluation, Preclinical; drug screening; dyslipidemia; Fructose - adverse effects; Gene Expression Regulation - drug effects; Gene Regulation; Genes, Reporter - genetics; Humans; Hypolipidemic Agents - pharmacology; ligand; Ligands; nuclear receptor; peroxisome proliferator-activated receptor (PPAR); PPAR alpha - genetics; PPAR alpha - metabolism; Rats; Tet-off system; transcription regulation; triglyceride; peroxisome proliferator-activated receptor (PPAR); triglyceride; transcription regulation; cell biology; drug screening; chemical screening system; Tet-off system; nuclear receptor; dyslipidemia; ligand
• ISSN: 0021-9258; 1083-351X
• DOI: 10.1074/jbc.RA118.002077

Peroxisome proliferator–activated receptor α (PPARα) is a ligand-activated transcription factor that belongs to the superfamily of nuclear hormone receptors. PPARα is mainly expressed in the liver, where it activates fatty acid oxidation and lipoprotein metabolism and improves plasma lipid profiles. Therefore, PPARα activators are often used to treat patients with dyslipidemia. To discover additional PPARα activators as potential compounds for use in hypolipidemic drugs, here we established human hepatoblastoma cell lines with luciferase reporter expression from the promoters containing peroxisome proliferator–responsive elements (PPREs) and tetracycline-regulated expression of full-length human PPARα to quantify the effects of chemical ligands on PPARα activity. Using the established cell-based PPARα-activator screening system to screen a library of >12,000 chemical compounds, we identified several hit compounds with basic chemical skeletons different from those of known PPARα agonists. One of the hit compounds, a 1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid derivative we termed compound 3, selectively up-regulated PPARα transcriptional activity, leading to PPARα target gene expression both in vitro and in vivo. Of note, the half-maximal effective concentrations of the hit compounds were lower than that of the known PPARα ligand fenofibrate. Finally, fenofibrate or compound 3 treatment of high fructose–fed rats having elevated plasma triglyceride levels for 14 days indicated that compound 3 reduces plasma triglyceride levels with similar efficiency as fenofibrate. These observations raise the possibility that 1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid derivatives might be effective drug candidates for selective targeting of PPARα to manage dyslipidemia.